COMT Val 108/158 Met polymorphism and treatment response to aripiprazole in patients with acute schizophrenia

Figures & data

Table 1 Comparisons among the 3 genotypes

Genotype	Val/Val group (n=23)	Val/Met group (n=13)	Met/Met group (n=4)	p-value
At baseline
Age (years)	41.6±11.9	43.5±14.2	35.7±2.1	0.621a
Sex, male/female	13/10	9/4	3/1	0.648b
Duration of illness (years)	10.0±9.6	13.7±14.2	8.0±7.0	0.576a
PANSS total	105.1±13.2	109.5±15.1	113.8±10.6	0.412a
PANSS positive	28.1±4.9	28.5±3.5	27.3±2.5	0.867a
PANSS negative	23.8±5.6	24.8±6.4	28.3±6.5	0.390a
PANSS general	53.2±7.7	55.9±9.3	59.5±7.2	0.305a
CGI-severity	5.5±0.5	5.5±0.8	5.5±0.6	0.983a
Plasma HVA level (ng/mL)	17.0±7.1	19.1±7.9	14.1±5.6	0.455a
Plasma MHPG level (ng/mL)	11.3±5.3	13.9±7.6	7.9±3.3	0.195a
At endpoint
Dose of aripiprazole (mg/d)	22.0±7.4	26.8±4.0	26.0±3.5	0.097a
Responders/nonresponders	10/13	3/10	3/1	0.157b
PANSS total	83.5±17.8	92.2±22.1	67.3±24.0	0.094a
PANSS positive	20.6±6.5	23.0±7.0	14.8±5.9	0.107a
PANSS negative	20.6±5.5	22.2±6.8	20.3±9.2	0.734a
PANSS general	42.3±8.1	46.9±11.8	33.3±12.3	0.058a
CGI-severity	3.8±1.4	4.2±1.4	2.5±1.7	0.119a
CGI-improvement	2.7±1.1	3.0±1.1	1.5±1.0	0.061a
Plasma HVA level (ng/mL)	16.8±11.0	15.4±7.4	19.6±10.6	0.759a
Plasma MHPG level (ng/mL)	7.9±3.3	8.6±3.9	6.5±1.9	0.552a

Note:

a One-way ANOVA,

b Pearson’s χ² test.

Abbreviations: PANSS, Positive and Negative Syndrome Scale; CGI, Clinical Global Impression; HVA, homovanillic acid; ANOVA, analysis of variance.

Figure 1 A mean change in PANSS total, positive, negative, and general psychopasology scores at baseline and 6 weeks.

Notes: (A) Genotype × time interaction on PANSS total score (F=5.296; p=0.009). (B) Genotype × time interaction on PANSS positive score (F=2.493; p=0.096). (C) Genotype × time interaction on PANSS negative score (F=2.941; p=0.065). (D) Genotype × time interaction on PANSS general psychopathology score (F=5.741; p=0.007).
Abbreviation: PANSS, Positive and Negative Syndrome Scale.

Table S1 Comparisons between responders and nonresponders

Response	Responders (n=16)	Nonresponders (n=24)	p-value
At baseline
Age (years)	40.3±12.0	42.9±12.1	0.644a
Sex, male/female	8/8	17/7	0.182b
Duration of illness (years)	11.8±11.1	10.9±11.2	0.981a
PANSS total	107.1±9.2	107.6±16.1	0.053a
PANSS positive	27.5±3.8	28.6±4.5	0.750a
PANSS negative	24.9±4.2	24.4±6.9	0.080a
PANSS general	54.6±7.3	54.8±9.0	0.359a
CGI-severity	5.6±0.5	5.5±0.7	0.214a
Plasma HVA level (ng/mL)	17.1±6.5	17.6±7.8	0.466a
Plasma MHPG level (ng/mL)	11.5±6.0	12.0±6.3	0.608a
At endpoint
Dose of aripiprazole (mg/d)	21.3±6.2	26.4±5.7	0.618a
Genotype groups (ValVal/ValMet/MetMet)	10/3/3	13/10/1	0.157b
PANSS total	67.8±10.1	96.0±17.9	0.046a
PANSS positive	15.1±3.2	24.5±5.9	0.009a
PANSS negative	17.8±2.9	23.3±6.9	0.020a
PANSS general	34.9±5.5	48.3±9.2	0.056a
CGI-severity	2.6±0.7	4.7±1.2	0.006a
CGI-improvement	1.5±0.5	3.5±0.5	0.000a
Plasma HVA level (ng/mL)	12.7±3.7	19.3±11.5	0.006a
Plasma MHPG level (ng/mL)	6.3±1.8	9.1±3.8	0.004a

Notes:

a Student’s t-test (unpaired).

b Pearson’s χ² test.

Abbreviations: PANSS, Positive and Negative Syndrome Scale; CGI, Clinical Global Impression; HVA, homovanillic acid.